Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences (GLS) by paying $2 million in cash, issuing 25 million shares of common stock, and assuming a $1 million promissory note. The transaction includes an additional $135,000 payment to the seller. GLS is developing GV104 for opioid-induced respiratory depression and GV023 for inflammatory conditions. Concurrently, Hepion appointed Sireesh Appajosyula as Chief Executive Officer and Gary Stetz as Chief Financial Officer, effective October 9, 2026. The company operates in the biotechnology sector.
